TY - JOUR
T1 - Papain-like protease regulates SARS-CoV-2 viral spread and innate immunity
AU - Shin, Donghyuk
AU - Mukherjee, Rukmini
AU - Grewe, Diana
AU - Bojkova, Denisa
AU - Baek, Kheewoong
AU - Bhattacharya, Anshu
AU - Schulz, Laura
AU - Widera, Marek
AU - Mehdipour, Ahmad Reza
AU - Tascher, Georg
AU - Geurink, Paul P.
AU - Wilhelm, Alexander
AU - van der Heden van Noort, Gerbrand J.
AU - Ovaa, Huib
AU - Müller, Stefan
AU - Knobeloch, Klaus Peter
AU - Rajalingam, Krishnaraj
AU - Schulman, Brenda A.
AU - Cinatl, Jindrich
AU - Hummer, Gerhard
AU - Ciesek, Sandra
AU - Dikic, Ivan
N1 - Publisher Copyright:
© 2020, The Author(s), under exclusive licence to Springer Nature Limited.
PY - 2020/11/26
Y1 - 2020/11/26
N2 - The papain-like protease PLpro is an essential coronavirus enzyme that is required for processing viral polyproteins to generate a functional replicase complex and enable viral spread1,2. PLpro is also implicated in cleaving proteinaceous post-translational modifications on host proteins as an evasion mechanism against host antiviral immune responses3–5. Here we perform biochemical, structural and functional characterization of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) PLpro (SCoV2-PLpro) and outline differences with SARS-CoV PLpro (SCoV-PLpro) in regulation of host interferon and NF-κB pathways. SCoV2-PLpro and SCoV-PLpro share 83% sequence identity but exhibit different host substrate preferences; SCoV2-PLpro preferentially cleaves the ubiquitin-like interferon-stimulated gene 15 protein (ISG15), whereas SCoV-PLpro predominantly targets ubiquitin chains. The crystal structure of SCoV2-PLpro in complex with ISG15 reveals distinctive interactions with the amino-terminal ubiquitin-like domain of ISG15, highlighting the high affinity and specificity of these interactions. Furthermore, upon infection, SCoV2-PLpro contributes to the cleavage of ISG15 from interferon responsive factor 3 (IRF3) and attenuates type I interferon responses. Notably, inhibition of SCoV2-PLpro with GRL-0617 impairs the virus-induced cytopathogenic effect, maintains the antiviral interferon pathway and reduces viral replication in infected cells. These results highlight a potential dual therapeutic strategy in which targeting of SCoV2-PLpro can suppress SARS-CoV-2 infection and promote antiviral immunity.
AB - The papain-like protease PLpro is an essential coronavirus enzyme that is required for processing viral polyproteins to generate a functional replicase complex and enable viral spread1,2. PLpro is also implicated in cleaving proteinaceous post-translational modifications on host proteins as an evasion mechanism against host antiviral immune responses3–5. Here we perform biochemical, structural and functional characterization of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) PLpro (SCoV2-PLpro) and outline differences with SARS-CoV PLpro (SCoV-PLpro) in regulation of host interferon and NF-κB pathways. SCoV2-PLpro and SCoV-PLpro share 83% sequence identity but exhibit different host substrate preferences; SCoV2-PLpro preferentially cleaves the ubiquitin-like interferon-stimulated gene 15 protein (ISG15), whereas SCoV-PLpro predominantly targets ubiquitin chains. The crystal structure of SCoV2-PLpro in complex with ISG15 reveals distinctive interactions with the amino-terminal ubiquitin-like domain of ISG15, highlighting the high affinity and specificity of these interactions. Furthermore, upon infection, SCoV2-PLpro contributes to the cleavage of ISG15 from interferon responsive factor 3 (IRF3) and attenuates type I interferon responses. Notably, inhibition of SCoV2-PLpro with GRL-0617 impairs the virus-induced cytopathogenic effect, maintains the antiviral interferon pathway and reduces viral replication in infected cells. These results highlight a potential dual therapeutic strategy in which targeting of SCoV2-PLpro can suppress SARS-CoV-2 infection and promote antiviral immunity.
UR - http://www.scopus.com/inward/record.url?scp=85088782038&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85088782038&partnerID=8YFLogxK
U2 - 10.1038/s41586-020-2601-5
DO - 10.1038/s41586-020-2601-5
M3 - Article
C2 - 32726803
AN - SCOPUS:85088782038
SN - 0028-0836
VL - 587
SP - 657
EP - 662
JO - Nature
JF - Nature
IS - 7835
ER -